Continuous, hyperfractionated, accelerated radiotherapy (CHART): an interim report upon late morbidity.

Continuous, hyperfractionated, accelerated radiotherapy (CHART) has given high levels of tumour control in advanced head and neck and bronchial carcinomas. In general, late changes have appeared less than after conventional radiotherapy but despite a prediction of reduced risk of spinal cord damage, two cases of radiation myelitis have presented. The possible causes are considered and a reduction in permitted spinal cord dose has been made.